|
|
More than 29 million Americans are living with diabetes, and 86 million are living with prediabetes, a serious health condition that increases a person’s risk of type 2 diabetes and other chronic diseases. As cited by the CDC, type 2 diabetes can result in an increased risk of the following:
|
Uncovering novel roles of glucagon physiology
We utilize genetic and dietary rodent models of these disease states, as well as intensive molecular and biochemical analyses in cell models. Our goal is to dissect the interactions between the brain and circulating hormones that regulate energy, glucose and lipid metabolism in peripheral tissues such as muscle, liver, and fat. This outlook provides us the opportunity to study metabolic regulation and interactions in multiple tissues from the cell to the intact organism. Many of the projects in the Habegger group investigate novel pharmacological or surgical therapies against diabetes and obesity in rodent models. Current projects include 1) the novel aspects of glucagon biology including its role in energy balance, glucose metabolism, and the adaptive response to exercise and 2) CNS integration of nutrient sensing.
|
Funding sources
Honors/Awards
2018- The American Society for Nutrition’s Bio-Serv Award in Experimental Animal Nutrition
2017- Pittman Scholar in the UAB School of Medicine
2016- ADA 76th Scientific Sessions, President’s Oral Session: Glucagon Stimulates Energy Expenditure and Reduces Obesity via Hepatic Farnesoid X Receptor in Mice.
2016- Nominee - Helmholtz Young Investigator Diabetes Award
2016- UAB-CFAR Early Career Investigator Award
2014- Paper of the Year – Treatment with Fibroblast Growth Factor 21 or Exendin-4 rescues leptin sensitivity in diet induced obese mice.
2013- Early Investigator Award. Cincinnati Diabetes and Obesity Center
2017- Pittman Scholar in the UAB School of Medicine
2016- ADA 76th Scientific Sessions, President’s Oral Session: Glucagon Stimulates Energy Expenditure and Reduces Obesity via Hepatic Farnesoid X Receptor in Mice.
2016- Nominee - Helmholtz Young Investigator Diabetes Award
2016- UAB-CFAR Early Career Investigator Award
2014- Paper of the Year – Treatment with Fibroblast Growth Factor 21 or Exendin-4 rescues leptin sensitivity in diet induced obese mice.
2013- Early Investigator Award. Cincinnati Diabetes and Obesity Center